Cargando…

Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort

BACKGROUND: The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) has changed dramatically with the introduction and widespread use of HER2-targeted therapies. However, there is relatively limited real-world information on patterns of use, effectiveness and sa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daniels, Benjamin, Lord, Sarah J, Kiely, Belinda E, Houssami, Nehmat, Haywood, Philip, Lu, Christine Y, Ward, Robyn L, Pearson, Sallie-Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278255/ https://www.ncbi.nlm.nih.gov/pubmed/28119394 http://dx.doi.org/10.1136/bmjopen-2016-014439

Ejemplares similares

Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
por: Daniels, Benjamin, et al.
Publicado: (2021)

Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Metastatic breast cancer incidence, site and survival in Australia, 2001–2016: a population-based health record linkage study protocol
por: Lord, Sarah J, et al.
Publicado: (2019)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Long term risk of distant metastasis in women with non‐metastatic breast cancer and survival after metastasis detection: a population‐based linked health records study
por: Lord, Sarah (Sally) J, et al.
Publicado: (2022)

Trastuzumab use in older patients with HER2-positive metastatic breast cancer: outcomes and treatment patterns in a whole-of-population Australian cohort (2003–2015)
por: Daniels, Benjamin, et al.
Publicado: (2019)

Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
por: Tang, Monica, et al.
Publicado: (2019)

Correction: Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)
por: Tang, Monica, et al.
Publicado: (2020)

Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early through late stage HER2-positive breast cancer (HER2BC)
por: Daniels, Benjamin, et al.
Publicado: (2017)

De novo and recurrent metastatic breast cancer – A systematic review of population-level changes in survival since 1995
por: Lord, SJ, et al.
Publicado: (2022)

Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013–2016
por: Daniels, Benjamin, et al.
Publicado: (2020)

Evaluation of radiographers’ mammography screen-reading accuracy in Australia
por: Debono, Josephine C, et al.
Publicado: (2015)

Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?
por: Prior, Lisa, et al.
Publicado: (2017)

Rates of reoperation after breast conserving cancer surgery in Western Australia before and after publication of the SSO-ASTRO margins guideline
por: Marinovich, M. Luke, et al.
Publicado: (2023)

Overdiagnosis of breast cancer in population screening: does it make breast screening worthless?
por: Houssami, Nehmat
Publicado: (2017)

Can population breast screening programs be leveraged to reduce the burden of breast cancer?
por: Houssami, Nehmat
Publicado: (2021)

Screening women with a personal history of breast cancer: overview of the evidence on breast imaging surveillance
por: Houssami, Nehmat, et al.
Publicado: (2018)

The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening
por: Houssami, Nehmat, et al.
Publicado: (2017)

Reflections from Women with an Interval Breast Cancer Diagnosis: A Qualitative Analysis of Open Disclosure in the BreastScreen Western Australia Program
por: Claringbold, Lily, et al.
Publicado: (2023)

General practitioners’ (GPs) understanding and views on breast density in Australia: a qualitative interview study
por: Nickel, Brooke, et al.
Publicado: (2021)

Comparison of claims from high–drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis
por: Tadrous, Mina, et al.
Publicado: (2021)

Staging the axilla in women with breast cancer: the utility of preoperative ultrasound-guided needle biopsy
por: Houssami, Nehmat, et al.
Publicado: (2014)

Towards consensus on managing high mammographic density in population breast screening?
por: Tagliafico, Alberto Stefano, et al.
Publicado: (2023)

Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study
por: Pearce, Alison, et al.
Publicado: (2017)

Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ
por: Morrow, Monica, et al.
Publicado: (2016)

A population-based study of breast cancer prevalence in Australia: predicting the future health care needs of women living with breast cancer
por: Yu, Xue Qin, et al.
Publicado: (2014)

Changes in systemic cancer therapy in Australia during the COVID-19 pandemic: a population-based study
por: Tang, Monica, et al.
Publicado: (2021)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

Exceptional Responses to Standard Therapy in a Patient with Metastatic HER2-Positive Breast Cancer
por: Nieder, Carsten, et al.
Publicado: (2017)

HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
por: Cavalieri, Stefano, et al.
Publicado: (2023)

Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies
por: Bergado-Báez, Gretchen, et al.
Publicado: (2022)

Artificial intelligence (AI) to enhance breast cancer screening: protocol for population-based cohort study of cancer detection
por: Marinovich, M Luke, et al.
Publicado: (2022)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Li, Yi, et al.
Publicado: (2021)

HER2 Status in RAS and BRAF Wild-Type Metastatic Colorectal Cancer: A Portuguese Study
por: Fraga, Teresa, et al.
Publicado: (2023)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

The Potential of panHER Inhibition in Cancer
por: Wang, Xiaochun, et al.
Publicado: (2015)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Comparison of Two Chemotherapy Regimens After First-Line Treatment for HER2-Negative Metastatic Gastric Cancer
por: Urakçı, Zuhat, et al.
Publicado: (2023)

Choosing wisely? Quantifying the extent of three low value psychotropic prescribing practices in Australia
por: Brett, Jonathan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_li45de39u7cs59jlm3jtun6d6v